Endogenous opioid system dysregulation in depression: implications for new therapeutic approaches | Molecular Psychiatry
Frontiers | The Kappa Opioid Receptor: From Addiction to Depression, and Back
Kappa Opioid Receptors in the Pathology and Treatment of Major Depressive Disorder | SpringerLink
Mixed Kappa/Mu Partial Opioid Agonists as Potential Treatments for Cocaine Dependence - ScienceDirect
Opioid receptor modulation of neural circuits in depression: What can be learned from preclinical data? - ScienceDirect
Opioid receptor modulation of neural circuits in depression: What can be learned from preclinical data? - ScienceDirect
Peripheral acting Mu opioid receptor antagonists in the treatment of the opioid-induced constipation: review
Opioid receptor modulation of neural circuits in depression: What can be learned from preclinical data? - ScienceDirect
Kappa Opioid Receptors in the Pathology and Treatment of Major Depressive Disorder | SpringerLink
Methylnaltrexone Mechanisms of Action and Effects on Opioid Bowel Dysfunction and Other Opioid Adverse Effects - Chun-Su Yuan, 2007
Data-driven analysis of kappa opioid receptor binding in major depressive disorder measured by positron emission tomography | Translational Psychiatry
Frontiers | Opioid Receptor-Mediated Regulation of Neurotransmission in the Brain
PDF) Major Depressive Disorder and Kappa Opioid Receptor Antagonists
Opioid receptors: drivers to addiction? | Nature Reviews Neuroscience
Some Actions of Arylacetamides in the Heart and Cardiovascular System | Download Table
Frontiers | The Kappa Opioid Receptor: From Addiction to Depression, and Back
Novel Mixed NOP/Opioid Receptor Peptide Agonists | Journal of Medicinal Chemistry
Antidepressant-like Effects of Buprenorphine are Mediated by Kappa Opioid Receptors | Neuropsychopharmacology
Pharmacology of Opioids: What Practitioners Need to Know
Frontiers | The Kappa Opioid Receptor: From Addiction to Depression, and Back
Signaling Properties of Structurally Diverse Kappa Opioid Receptor Ligands: Toward in Vitro Models of in Vivo Responses | ACS Chemical Neuroscience
Frontiers | A Review of the Therapeutic Potential of Recently Developed G Protein-Biased Kappa Agonists
Major Depressive Disorder and Kappa Opioid Receptor
PDF) Opioids in COVID-19: Two Sides of a Coin
PDF) Targeting opioid receptor signalling in depression: do we need selective kappa opioid receptor antagonists?
